Clinical Policy: Somatropin (Human Growth Hormone)
Reference Number: GA.PMN.27
Effective Date: 08/2020
Last Review Date: 07/2021
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The following human growth hormone (hGH) formulations require prior authorization:
- hGH analogs: somapacitan-beco (Sogroya®)
- Recombinant hGH (rhGH) formulations: somatropin (Genotropin®, Humatrope®, Norditropin®, Nutropin AQ®, Omnitrope®, Saizen®, Serostim®, Zomacton®, Zorbtive®)

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GHD</td>
<td>PWS</td>
</tr>
<tr>
<td>Sogroya</td>
<td>GF</td>
<td>GF</td>
</tr>
<tr>
<td>Genotropin</td>
<td>GF</td>
<td>GF</td>
</tr>
<tr>
<td>Humatrope</td>
<td>SS/GF</td>
<td>SS/GF</td>
</tr>
<tr>
<td>Norditropin</td>
<td>GF</td>
<td>GF</td>
</tr>
<tr>
<td>NutropinAQ</td>
<td>GF</td>
<td>GF</td>
</tr>
<tr>
<td>Omnitrope</td>
<td>GF</td>
<td>GF</td>
</tr>
<tr>
<td>Saizen</td>
<td>GF</td>
<td></td>
</tr>
<tr>
<td>Serostim</td>
<td>GF</td>
<td></td>
</tr>
<tr>
<td>Zomacton</td>
<td>GF</td>
<td>SS</td>
</tr>
<tr>
<td>Zorbtive</td>
<td>GF</td>
<td></td>
</tr>
</tbody>
</table>


FDA Approved Indication(s)
**hGH Analogs:**
Sogroya is indicated for:
- Replacement of endogenous GH in adults with GHD

**rhGH Formulations:**
Genotropin is indicated for treatment of:
- Children with GF due to GHD, PWS, SGA, TS, and ISS.
- Adults with either childhood-onset (CO) or adult-onset (AO) GHD.
Humatrope is indicated for treatment of:
- Children with SS or GF associated with GHD, TS, ISS, SHOX deficiency, and failure to catch up in height after SGA birth.
- Adults with either CO or AO GHD.

Norditropin FlexPro is indicated for the treatment of:
- Children with GF due to GHD, SS associated with NS, SS associated with TS, SS born SGA with no catch-up growth by age 2 to 4 years, ISS, and GF due to PWS.
- Adults with either CO or AO GHD.

Nutropin AQ is indicated for the treatment of:
- Children with GF due to GHD, ISS, TS, and CKD up to the time of renal transplantation.
- Adults with either CO or AO GHD.

Omnitrope is indicated for the treatment of:
- Children with GF due to GHD, PWS, SGA, TS, and ISS.
- Adults with either CO or AO GHD.

Saizen is indicated for:
- Children with GF due to GHD.
- Adults with either CO or AO GHD.

Serostim is indicated for treatment of:
- HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance.

Zomacton is indicated for:
- Treatment of pediatric patients who have GF due to inadequate secretion of normal endogenous GH, SS associated with TS, ISS, SS or GF in SHOX deficiency, and SS born SGA with no catch-up growth by 2 years to 4 years.
- Replacement of endogenous GH in adults with GHD.

Zorbtive is indicate for treatment of:
- SBS in adult patients receiving specialized nutritional support.

**Policy/Criteria**
*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*
D. Chronic Kidney Disease with Growth Failure - Children
E. Born Small for Gestational Age with Short Stature/Growth Failure - Children
F. Growth Hormone Deficiency - Adults and Transition Patients *(closed epiphyses)*
G. Short Bowel Syndrome - Adults
H. HIV-Associated Wasting/Cachexia - Adults
I. Other diagnoses/indications

II. Continuing Approval Criteria
   A. All Pediatric Indications *(open epiphyses)*
   B. Growth Hormone Deficiency - Adults and Transition Patients *(closed epiphyses)*
   C. Short Bowel Syndrome - Adults
   D. HIV-Associated Wasting/Cachexia - Adults
   E. Other diagnoses/indications

III. Diagnoses/Indications for which coverage is NOT authorized:

IV. Appendices

V. Dosage and Administration

VI. Product Availability

VII. References

It is the policy of health plans affiliated with Centene Corporation® that somatropin (recombinant human growth hormone (rhGH)) is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Growth Hormone Deficiency with Neonatal Hypoglycemia *(off-label)* (must meet all):
      1. Diagnosis of neonatal hypoglycemia due to GHD;
      2. Prescribed by or in consultation with a pediatric endocrinologist;
      3. Age ≤ 1 month;
      4. Serum GH concentration ≤ 5 µg/L;
      5. Member meets (a or b):
         a. Imaging shows hypothalamic-pituitary abnormality;
         b. Deficiency of ≥ 1 anterior pituitary hormone other than GH (e.g., ACTH, TSH, LH, FSH, prolactin);
      6. The requested product is not prescribed concurrently with Increlex® (mecasermin);
      7. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
      8. Dose does not exceed 0.30 mg/kg per week.
      Approval duration: 12 months
   B. Growth Hormone Deficiency with Short Stature/Growth Failure - Children *(open epiphyses)* (must meet all):
      1. Diagnosis of GHD;
      2. Prescribed by or in consultation with a pediatric endocrinologist;
      3. Age < 18 years;
      4. If age > 10 years, open epiphysis on x-ray;
      5. Member meets (a or b):
         a. Low insulin-like growth factor (IGF)-I serum level;
b. Low insulin-like growth factor binding protein (IGFBP)-3 serum level;

6. Member meets (a, b, c, d, or e):
   a. Two GH stimulation tests with peak serum levels ≤ 10 µg/mL (e.g., stimulants: arginine, clonidine, glucagon);
   b. Deficiency of ≥ 3 pituitary hormones (i.e., ACTH, TSH, LH, FSH, prolactin);
   c. Surgery or radiotherapy to the hypothalamic-pituitary region;
   d. Imaging shows hypothalamic-pituitary abnormality;
   e. GHD-specific mutation (e.g., POU1F1, PROP1, LHX3, LHX4, HESX1, OTX2, TBX19, SOX2, SOX3, GLI2, GHRHR, GH1);

7. Member meets (a or b):
   a. SS: height < -2 SD below the mean for age and gender (SD and height within the last 90 days required);
   b. GF: growth has slowed by more than 1 SD in ≥ 6 months (SD and 2 heights ≥ 6 months apart within the last year required);

8. The requested product is not prescribed concurrently with Increlex (mecasermin);

9. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;

10. Dose does not exceed 0.30 mg/kg per week.

**Approval duration: 12 months**

**C. Genetic Disorders with Short Stature/Growth Failure - Children** (must meet all):

1. Diagnosis of PWS, TS, NS, or SHOX deficiency confirmed by a genetic test;
2. Prescribed by or in consultation with a pediatric endocrinologist;
3. Age < 18 years;
4. If age > 10 years, open epiphysis on x-ray;
5. Member meets (a or b):
   a. SS: height < -2 SD (< -1.5 SD if TS) below the mean for age and gender (SD and height within the last 90 days required);
   b. GF: growth has slowed by more than 1 SD in ≥ 6 months (SD and 2 heights ≥ 6 months apart within the last year required);
6. The requested product is not prescribed concurrently with Increlex (mecasermin);
7. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
8. Request meets one of the following (a, b, or c):
   a. PWS: Dose does not exceed 0.24 mg/kg per week;
   b. TS, NS: Dose does not exceed 0.5 mg/kg per week;
   c. SHOX deficiency: Dose does not exceed 0.35 mg/kg per week.

**Approval duration: 12 months**

**D. Chronic Kidney Disease with Growth Failure – Children** (must meet all):

1. Diagnosis of CKD;
2. Prescribed by or in consultation with a pediatric endocrinologist or nephrologist;
3. Age < 18 years;
4. If age > 10 years, open epiphysis on x-ray;
5. Member meets (a, b, c, or d):
   a. GFR < 60 mL/min per 1.73 m² for ≥ 3 months;
b. Dialysis dependent;
c. Diagnosis of nephropathic cystinosis;
d. History of kidney transplant ≥ 1 year ago;
6. Member meets (a or b):
   a. SS: height < -2 SD below the mean for age and gender (SD and height within the last 90 days required);
   b. GF: growth has slowed by more than 1 SD in ≥ 6 months (SD and 2 heights ≥ 6 months apart within the last year required);
7. The requested product is not prescribed concurrently withIncrelex (mecasermin);
8. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
9. Dose does not exceed 0.35 mg/kg per week.
Approval duration: 12 months

E. Born Small for Gestational Age with Short Stature/Growth Failure - Children (must meet all):
1. Diagnosis of SGA:
2. Prescribed by or in consultation with a pediatric endocrinologist;
3. Age ≥ 2 years and < 18 years;
4. If age > 10 years, open epiphysis on x-ray;
5. Member meets (a and b):
   a. Birth weight or length < -2 SD below the mean for gestational age (birth weight and length, with SD, required);
   b. Current height < -2 SD below the mean for age and gender (measured within the last year at ≥ 2 years of age - age, SD, and height required);
6. The requested product is not prescribed concurrently with Increlex (mecasermin);
7. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
8. Dose does not exceed 0.48 mg/kg per week.
Approval duration: 12 months

F. Growth Hormone Deficiency – Adults and Transition Patients (closed epiphyses) (must meet all):
1. Diagnosis of GHD;
2. Prescribed by or in consultation with an endocrinologist;
3. Age ≥ 18 years OR closed epiphysis on x-ray;
4. Member has NOT received somatropin therapy for ≥ 1 month prior to GH/IGF-I testing as outlined below;
5. Member meets (a, b, or c):
   a. Two fasting a.m. GH stimulation tests with peak serum levels ≤ 5 µg/mL (accepted stimulants: Macrilen™ [macimorelin] or combination of 2 stimulants such as arginine + glucagon);
   b. Both of the following (i and ii):
      i. One fasting a.m. GH stimulation test with peak serum level ≤ 5 µg/ml (accepted stimulants: Macrilen [macimorelin] or combination of 2 stimulants such as arginine + glucagon);
ii. One low IGF-I serum level;
c. One low IGF-I serum level and (i, ii, or iii):
   i. Imaging shows hypothalamic-pituitary abnormality;
   ii. Deficiency of ≥ 3 pituitary hormones (i.e., ACTH, TSH, LH, FSH, prolactin);
   iii. GHD-specific mutation (e.g., POU1F1, PROP1, LHX3, LHX4, HESX1, OTX2, TBX19, SOX2, SOX3, GLI2, GHRHR, GH1);
6. The requested product is not prescribed concurrently with Increlex (mecasermin);
7. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
8. Dose does not exceed one of the following (a or b):
   a. For Sogroya: 8 mg once weekly;
   b. For somatropin formulations: 0.4 mg/day (may adjust by up to 0.2 mg/day every 4 weeks to maintain normal IGF-1 serum levels; doses > 1.6 mg/day would be uncommon).

Approval duration: 6 months

G. Short Bowel Syndrome (must meet all):
   1. Diagnosis of SBS;
   2. Prescribed by or in consultation with a gastroenterologist;
   3. Age ≥ 18 years;
   4. Patient is dependent upon and receiving intravenous nutrition;
   5. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
6. Dose does not exceed 8 mg per day.

Approval duration: up to 4 weeks total

H. HIV-Associated Wasting or Cachexia (must meet all):
   1. Diagnosis of HIV;
   2. Prescribed by or in consultation with a physician specializing in HIV management;
   3. Age ≥ 18 years;
   4. Unintentional weight loss of ≥ 10% in the last 12 months occurring while on antiretroviral therapy;
   5. Failure of at least 2 pharmacologic therapies from two separate drug classes (Appendix B) unless contraindicated or clinically adverse effects are experienced;
6. If request is NOT for Norditropin, Norditropin product excipients are contraindicated or member has experienced a clinically significant adverse effect to Norditropin;
7. Prescribed dose does not exceed 6 mg per day.

Approval duration: 6 months

I. Other diagnoses/indications
   1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.
II. Continued Therapy

A. All Pediatric Indications (open epiphyses) (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Age < 18 years OR open epiphysis on x-ray;
   3. Member meets (a or b):
      a. For diagnosis of neonatal hypoglycemia, when member has received somatropin therapy for ≥ 2 years, member’s height has increased ≥ 2 cm in the last year as documented by 2 height measurements taken no more than 1 year apart (dates and height measurements required);
      b. For all other pediatric diagnoses, member’s height has increased ≥ 2 cm in the last year as documented by 2 height measurements taken no more than 1 year apart (dates and height measurements required);
   4. If request is for a dose increase, request meets the one of the following (a, b, c, d, or e):
      a. GHD with or without neonatal hypoglycemia: New dose does not exceed 0.30 mg/kg per week;
      b. PWS: New dose does not exceed 0.24 mg/kg per week;
      c. TS, NS: New dose does not exceed 0.5 mg/kg per week;
      d. SHOX deficiency, CKD: New dose does not exceed 0.35 mg/kg per week;
      e. Born SGA: New dose does not exceed 0.48 mg/kg per week.

Approval duration: 12 months

B. Growth Hormone Deficiency - Adults and Transition Patients (closed epiphyses) (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. For IGF-1 test results and dosing (test conducted within the last 90 days) (a, b, or c):
      a. Low IGF-1 serum level (i or ii):
         i. For Sogroya: 8 mg once weekly;
         ii. For somatropin formulations: If request is for a dose increase, new dose does not exceed an incremental increase of more than 0.2 mg/day and a total dose of 1.6 mg/day;
      b. Normal IGF-1 serum level: Requested dose is for the same or lower dose;
      c. Elevated IGF-1 serum level: Requested dose has been titrated downward.

Approval duration: 12 months

C. Short Bowel Syndrome - Adults (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
   2. Member is responding positively to therapy;
   3. Member has not received the requested product for ≥ 4 weeks;
   4. If request is for a dose increase, new dose does not exceed 8 mg per day.

Approval duration: up to 4 weeks total
D. HIV-Associated Wasting/Cachexia - Adults (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
   2. Member is responding positively to therapy;
   3. Member has not received ≥ 12 months of therapy;
   4. If request is for a dose increase, new dose does not exceed 6 mg per day.

   **Approval duration: up to 12 months total**

E. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy.
   2. Refer to CP.PMN.53 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.
   B. Idiopathic short stature (ISS);
   C. Constitutional delay of growth and puberty (i.e., constitutional growth delay; the member’s growth rate is delayed compared to chronological age but appropriate for bone age as determined by x-ray);
   D. Familial (genetic) short stature (i.e., height velocity and bone age, as determined by x-ray, are within the normal range and one or both parents are short);
   E. Adult short stature or altered body habitus associated with antiviral therapy (other than HIV-associated wasting or cachexia);
   F. Obesity treatment or enhancement of body mass/strength for non-medical reasons (e.g., athletic gains).

IV. Appendices/General Information

   **Appendix A: Abbreviation/Acronym Key**
   - CKD: chronic kidney disease
   - FDA: Food and Drug Administration
   - GFR: glomerular filtration rate
   - GH: growth hormone
   - GHD: growth hormone deficiency
   - HIV: human immunodeficiency virus
   - IGF-1: insulin-like growth factor-1
   - IGFBP-3: insulin-like growth factor binding protein-3
   - ISS: idiopathic short stature
   - NS: Noonan syndrome
   - PWS: Prader-Willi syndrome
   - rhGH: recombinant human growth hormone
   - SBS: short bowel syndrome
   - SD: standard deviation
   - SGA: small for gestational age
   - SHOX: short stature homeobox-containing gene
   - TS: Turner syndrome
Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Appetite Stimulants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Megestrol (Megace®)</td>
<td>400 - 800 mg PO daily (10 – 20 ml/day)</td>
<td>800 mg/day</td>
</tr>
<tr>
<td>Dronabinol (Marinol®)</td>
<td>2.5 mg PO bid</td>
<td>20 mg/day</td>
</tr>
<tr>
<td><strong>Testosterone Replacement Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone enanthate or cypionate</td>
<td>50 - 400 mg IM Q2 – 4 wks</td>
<td>400 mg Q 2 wks</td>
</tr>
<tr>
<td>Androderm® (testosterone transdermal)</td>
<td>2.5 – 7.5 mg patch applied topically QD</td>
<td>7.5 mg/day</td>
</tr>
<tr>
<td>Androgel® (testosterone gel)</td>
<td>5 - 10 gm gel (delivers 50 – 100 mg testosterone) applied topically QD</td>
<td>10 gm/day gel (100 mg/day testosterone)</td>
</tr>
<tr>
<td>Testim® (testosterone gel)</td>
<td>5 - 10 gm gel (delivers 50 – 100 mg testosterone) applied topically QD</td>
<td>10 gm/day gel (100 mg/day testosterone)</td>
</tr>
<tr>
<td><strong>Anabolic Steroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxandrolone (Oxandrin®)</td>
<td>2.5 – 20 mg PO /day</td>
<td>20 mg/day</td>
</tr>
<tr>
<td>Nandrolone decanoate</td>
<td>100 mg IM Q week</td>
<td>100 mg Q wk</td>
</tr>
<tr>
<td><strong>Nausea/Vomiting Treatments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>10 to 25 mg PO q4 to 6 hours prn</td>
<td>2,000 mg/day</td>
</tr>
<tr>
<td>perphenazine</td>
<td>8 to 16 mg/day PO in divided doses</td>
<td>64 mg/day</td>
</tr>
<tr>
<td>prochlorperazine</td>
<td>5 to 10 mg PO TID or QID</td>
<td>40 mg/day</td>
</tr>
<tr>
<td>promethazine</td>
<td>12.5 to 25 mg PO q4 to 6 hours prn</td>
<td>50 mg/dose; 100 mg/day</td>
</tr>
<tr>
<td>trimethobenzamide</td>
<td>300 mg PO TID or QID prn</td>
<td>1,200 mg/day</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Preferred status may be formulary-specific.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Acute critical illness
  - Children with PWS who are severely obese or have severe respiratory impairment (reports of sudden death)
  - Active malignancy
  - Product hypersensitivity
  - Active proliferative or severe non-proliferative diabetic retinopathy
  - Children with closed epiphyses
• Sogroya contraindications:
  o Acute critical illness
  o Active malignancy
  o Hypersensitivity to somapacitan-beco or excipients
• Active proliferative or severe non-proliferative diabetic retinopathy
• Boxed warning(s): none reported

Appendix D: Short Stature and Growth Failure
• For SS, the policy follows the World Health Organization (WHO) definition of > 2 SD below the mean for age and sex.¹
• For GF, the policy follows
  o Haymond et al (2013) and Rogol et al (2014) for height deceleration across two major percentiles representing a change of > 1 SD corrected for age and sex²³ and
  o the Growth Hormone Research Society (2000) for height velocity in the absence of SS that would prompt further investigation, namely, a height velocity > 2 SD below the mean over 1 year or > 1.5 SD below the mean sustained over 2 years for age and sex.⁴
• The Centers for Disease Control and Prevention (CDC) recommend WHO growth charts for infants and children age 0 to < 2 years and CDC growth charts for children age 2 years to < 20 years in the U.S.⁵
  o Based on CDC recommended growth chart data, SD approximations of major height percentiles falling below the mean are listed below:
    ▪ 2nd percentile: 2 SD below the mean
    ▪ 5th percentile: 1.5 SD below the mean
    ▪ 15th percentile: 1 SD below the mean
    ▪ 30th percentile: 0.5 SD below the mean
    ▪ 50th percentile: 0 SD mean
  o CDC recommended growth charts, data tables, and related information that may be helpful in assessing length, height and growth are available at the following link: https://www.cdc.gov/growthcharts/index.htm.

V. Dosage and Administration

### Pediatric Indications (Subcutaneous administration; weekly doses should be divided)

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotropin, Humatrope, Norditropin, Nutropin, Omnitrone, Saizen, Zomacton</td>
<td>GHD</td>
<td>G, O: 0.16 to 0.24 mg/kg/week H, Z: 0.18 to 0.30 mg/kg/week N: 0.17 to 0.24 mg/kg/week Nu: to 0.30 mg/kg/week S: 0.18 mg/kg/week</td>
<td>See dosing regimens</td>
</tr>
<tr>
<td>Genotropin, Norditropin, Omnitrope</td>
<td>PWS</td>
<td>G, N, O: 0.24 mg/kg/week</td>
<td>0.24 mg/kg/week</td>
</tr>
<tr>
<td>Genotropin, Humatrope, Norditropin, Omnitrope, Zomacton</td>
<td>SGA</td>
<td>G, O: to 0.48 mg/kg/week H, N, Z: to 0.47 mg/kg/week</td>
<td>0.48 mg/kg/week</td>
</tr>
<tr>
<td>Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Zomacton</td>
<td>TS</td>
<td>G, O: 0.33 mg/kg/week H, Nu, Z: to 0.375 mg/kg/week N: to 0.47 mg/kg/week</td>
<td>See dosing regimens</td>
</tr>
<tr>
<td>Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Zomacton</td>
<td>ISS</td>
<td>G, O, No: to 0.47 mg/kg/week H, Z: to 0.37 mg/kg/week Nu: to 0.30 mg/kg/week</td>
<td>See dosing regimens</td>
</tr>
<tr>
<td>Humatrope, Zomacton</td>
<td>SHOX</td>
<td>H, Z: 0.35 mg/kg/week</td>
<td>0.35 mg/kg/week</td>
</tr>
<tr>
<td>Norditropin</td>
<td>NS</td>
<td>0.46 mg/kg/week</td>
<td>0.46 mg/kg/week</td>
</tr>
<tr>
<td>Nutropin</td>
<td>CKD</td>
<td>0.35 mg/kg/week</td>
<td>0.35 mg/kg/week</td>
</tr>
</tbody>
</table>

### Adult Indications (Subcutaneous administration)

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton</td>
<td>GHD</td>
<td>0.4 mg/day - may adjust by increments up to 0.2 mg/day every 6 weeks to maintain normal IGF-1 serum levels.*</td>
<td>See dosing regimen</td>
</tr>
<tr>
<td>Serostim</td>
<td>HIV-associated wasting</td>
<td>0.1 mg/kg QOD or QD to 6 mg QD</td>
<td>6 mg/day up to 24 weeks</td>
</tr>
<tr>
<td>Sogroya</td>
<td>GHD</td>
<td>0.5 mg once weekly – increase by increments of 0.5-1.5 mg every 2-4 weeks based on clinical response and serum IGF-1 concentrations</td>
<td>8 mg/week</td>
</tr>
</tbody>
</table>

*Dosing regimen from Endocrine Society guidelines (Fleseriu, et al., 2016).

Adult GHD dosing should be substantially lower than that prescribed for children. Adult doses beyond 1.6 mg/day would be uncommon.
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zorbtive</td>
<td>SBS</td>
<td>0.1 mg/kg QD to 8 mg QD</td>
<td>8 mg/day up to 4 weeks</td>
</tr>
</tbody>
</table>

**Abbreviations:** G: genotropin, H: humatrope, N: norditropin, Nu: nutropin, O: omnitrope, S: saizen, Z: zomacton

### VI. Product Availability

#### hGH Analogs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sogroya</td>
<td>MD pen: 10 mg/1.5 mL</td>
</tr>
</tbody>
</table>

#### rhGH Formulations

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotropin lyophilized powder</td>
<td>Dual-chamber syringe: 5 mg, 12 mg</td>
</tr>
<tr>
<td>Genotropin Miniquick (without preservative)</td>
<td>Pen cartridge: 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, and 2.0 mg</td>
</tr>
<tr>
<td>Humatrope</td>
<td>Pen cartridge: 6 mg, 12 mg, 24 mg</td>
</tr>
<tr>
<td></td>
<td>Vial: 5mg</td>
</tr>
<tr>
<td>Norditropin Flexpro</td>
<td>Pen: 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL, 30 mg/3 mL</td>
</tr>
<tr>
<td>Nutropin AQ</td>
<td>NuSpin: 5 mg/2 mL, 10 mg/2 mL, 20 mg/2 mL</td>
</tr>
<tr>
<td>Omnitrope</td>
<td>Pen cartridge: 5 mg/1.5 mL, 10 mg/1.5 mL</td>
</tr>
<tr>
<td></td>
<td>Vial: 5.8 mg</td>
</tr>
<tr>
<td>Saizen</td>
<td>Pen cartridge: 8.8 mg</td>
</tr>
<tr>
<td></td>
<td>Vial: 5 mg, 8.8 mg</td>
</tr>
<tr>
<td>Serostim</td>
<td>Vial: 4 mg, 5 mg, 6 mg</td>
</tr>
<tr>
<td>Zomacton</td>
<td>Vial: 5 mg, 10 mg</td>
</tr>
<tr>
<td>Zorbtive</td>
<td>Vial: 8.8 mg</td>
</tr>
</tbody>
</table>

**SD:** single-dose, **MD:** multidose

### VII. References

**FDA Labels**


Compendia

Somatropin Therapy - Children

GHD - Adults and Transition Patients

Short Bowel Syndrome

HIV-Associated Wasting

Somatropin Product Comparative Data
Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2941</td>
<td>Injection, somatropin, 1 mg</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy created from CP.PHAR.55 Somatropin (Human Growth Hormone) to maintain preferencing and redirection to Norditropin instead of the new Centene redirection to Zomacton. Replaced Centene Logo with Peach State Health Plan Logo.</td>
<td>8/2020</td>
<td></td>
</tr>
<tr>
<td>Annual review. Added Sogroya FDA indications and dosing, formulations, throughout policy. Added coding implications. Updated references.</td>
<td>7/2021</td>
<td>7/2021</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or
regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.